Core Viewpoint - Silo Pharma, Inc. has received a Notice of Allowance for a patent that will enhance its intellectual property protection for its lead asset, SPC-15, which targets PTSD treatment [1][2] Group 1: Patent and Intellectual Property - The U.S. Patent and Trademark Office will issue a patent for biomarkers related to prophylactic treatments against stress-induced affective disorders, expected to be U.S. Patent No. 12,329,726 on June 17, 2025 [1][2] - This patent strengthens Silo's IP protection for SPC-15, an intranasal treatment for PTSD [2][3] Group 2: Product Development - SPC-15 is an intranasal serotonin 5-HT4 receptor agonist aimed at treating stress-induced psychiatric disorders, including PTSD and anxiety [4] - The product is eligible for the FDA's streamlined 505(b)(2) regulatory pathway, potentially accelerating its approval process [4] - Silo Pharma is preparing to initiate Phase 1 clinical trials for SPC-15 [3] Group 3: Company Overview - Silo Pharma focuses on developing treatments for underserved conditions such as stress-induced psychiatric disorders, chronic pain, and CNS diseases [5] - The company's portfolio includes other innovative programs like SP-26 for fibromyalgia and chronic pain, as well as preclinical assets targeting Alzheimer's disease and multiple sclerosis [5]

Core Insights - Silo Pharma, Inc. has approved the purchase of up to $1 million in Bitcoin as a treasury reserve asset to diversify its holdings and provide a digital store of value with significant upside potential [1][2] - The CEO of Silo Pharma stated that this strategic decision aims to safeguard against inflation and optimize long-term shareholder value [2] Company Overview - Silo Pharma, Inc. is a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems [1] - The company addresses underserved conditions such as stress-induced psychiatric disorders, chronic pain, and central nervous system diseases [2] - Silo's portfolio includes innovative programs targeting PTSD, fibromyalgia, chronic pain, Alzheimer's disease, and multiple sclerosis, with research conducted in collaboration with leading universities and laboratories [2]

Core Viewpoint - Silo Wellness Inc. is transitioning to "Born Defense," focusing on defense and national security investments, guided by the Just War Doctrine, aiming to end "forever wars" and promote responsible national self-defense [1][4]. Company Transition and Strategic Focus - Born Defense will invest in advanced defense technologies, including cybersecurity, autonomous systems, and advanced manufacturing, supporting Canada's defense sector growth in line with NATO's 2% GDP defense spending target by 2027 [2][6]. - The company plans to explore high-potential investments across North America and Europe, delivering ethical and scalable defense solutions [2]. Investment Strategy - The global defense market is projected to reach $676.64 billion by 2029, growing at a 6.4% CAGR, positioning Born Defense to capitalize on growth opportunities [5][6]. - The company aims to leverage strategic capital and deep industry networks to support innovative companies addressing modern security threats [5]. Geopolitical Context - Rising global tensions, including conflicts in Eastern Europe and cybersecurity threats, are driving demand for innovative defense solutions [6][7]. - Born Defense's commitment to ending "forever wars" aligns with the increasing investor interest in socially responsible opportunities [7]. Proposed Changes and Governance - The company will hold a shareholder meeting to approve the name change and elect a board with defense and national security expertise, resulting in a change of control [9]. - The completion of the proposed transaction is subject to various approvals, including financing and regulatory [10]. Divestment and Future Focus - The company plans to divest its psychedelic assets to focus resources on the defense industry, which is seen as having greater growth potential [11][13]. - There is an openness to explore investments in psychedelic therapy aligned with Department of Defense research for PTSD and traumatic brain injuries [11]. Funding and Compliance - Funding for necessary audits and listing statements has been secured, and the company is working to revoke a Cease Trade Order issued due to delayed financial filings [15].

Core Insights - Silo Pharma has entered into a service agreement with Resyca BV for a drug-device study of its lead asset SPC-15, aimed at treating PTSD through a microchip-based nasal spray system [1][2] - The study is expected to provide final device data and documentation necessary for the FDA IND submission planned for this year [2] - SPC-15 is a serotonin 5-HT4 receptor agonist targeting stress-induced psychiatric disorders, with potential eligibility for the FDA's streamlined 505(b)(2) regulatory pathway [3] Company Overview - Silo Pharma Inc. is a developmental stage biopharmaceutical company focused on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and CNS diseases [5] - The company's portfolio includes innovative programs such as SPC-15 for PTSD and SP-26 for fibromyalgia and chronic pain, along with preclinical assets targeting Alzheimer's disease and multiple sclerosis [5] Partner Overview - Resyca BV, founded in 2020, specializes in developing and manufacturing soft mist inhalation and nasal spray devices, utilizing proprietary micro-nozzle technology [4] - Resyca is a joint venture between Bespak Limited and Medspray Pharma BV, offering comprehensive services from early-stage development to commercial production [4]

Core Viewpoint - Silo Pharma, Inc. has successfully completed a public offering of 3,333,338 shares of common stock at a price of $0.60 per share, raising approximately $2 million in gross proceeds for general working capital purposes [1][2]. Group 1: Offering Details - The public offering includes Series A-1 and Series A-2 warrants, each with an exercise price of $0.60 per share [1]. - Series A-1 Warrants are exercisable upon issuance and expire five years thereafter, while Series A-2 Warrants expire eighteen months after issuance [1]. - H.C. Wainwright & Co. acted as the exclusive placement agent for the offering [2]. Group 2: Company Overview - Silo Pharma is a developmental stage biopharmaceutical company focused on addressing underserved conditions such as stress-induced psychiatric disorders, chronic pain, and central nervous system diseases [5]. - The company's portfolio includes innovative programs targeting PTSD, fibromyalgia, chronic pain, Alzheimer's disease, and multiple sclerosis [5]. - Research is conducted in collaboration with leading universities and laboratories [5].

Core Viewpoint - Silo Pharma, Inc. has announced a public offering of 3,333,338 shares of common stock at a price of $0.60 per share, along with associated warrants, aiming to raise approximately $2 million for general working capital purposes [1][2]. Group 1: Offering Details - The public offering includes 3,333,338 shares of common stock and two series of warrants (Series A-1 and Series A-2), each with an exercise price of $0.60 per share [1]. - The Series A-1 Warrants are exercisable upon issuance and will expire five years thereafter, while the Series A-2 Warrants will expire eighteen months after issuance [1]. - The closing of the offering is expected to occur on or about May 16, 2025, subject to customary closing conditions [1]. Group 2: Financial Aspects - The gross proceeds from the offering are expected to be approximately $2 million before deducting fees and expenses [2]. - The net proceeds will be used for general working capital purposes [2]. Group 3: Company Overview - Silo Pharma, Inc. is a developmental stage biopharmaceutical company focused on addressing underserved conditions such as stress-induced psychiatric disorders, chronic pain, and CNS diseases [5]. - The company's portfolio includes innovative programs targeting PTSD, fibromyalgia, chronic pain, Alzheimer's disease, and multiple sclerosis [5]. - Research is conducted in collaboration with leading universities and laboratories [5].

Core Insights - Silo Pharma, Inc. has engaged Veloxity Labs for bioanalysis to support the ongoing GLP-compliant toxicology study of its lead asset, SPC-15, which is an intranasal treatment for PTSD [1][2] - The company anticipates starting the FDA IND process for SPC-15 in 2025, with plans to proceed to a Phase 1 clinical trial upon IND approval [2] Company Overview - Silo Pharma is a developmental stage biopharmaceutical company focused on addressing underserved conditions such as stress-induced psychiatric disorders, chronic pain, and CNS diseases [3] - The company's portfolio includes innovative programs like SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis [3] - Research is conducted in collaboration with leading universities and laboratories [3]

Core Insights - Silo Pharma, Inc. has entered into an agreement with Frontage Laboratories for a 7-day safety and toxicology study of its lead asset SPC-15, an intranasal treatment for PTSD, as requested by the FDA [1][2] - The company is on track to submit an Investigational New Drug (IND) application to the FDA this year, with positive preclinical data expected to support this submission in 2025 [2] - Silo Pharma has an exclusive global license from Columbia University to develop, manufacture, and commercialize SPC-15 [3] Company Overview - Silo Pharma is a developmental stage biopharmaceutical company focused on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and CNS diseases [6] - The company's portfolio includes innovative programs such as SPC-15 for PTSD and SP-26 for fibromyalgia and chronic pain, along with preclinical assets targeting Alzheimer's disease and multiple sclerosis [6] Product Details - SPC-15 is an intranasal serotonin 5-HT4 receptor agonist aimed at treating stress-induced psychiatric disorders like PTSD and anxiety [4] - The product may qualify for the FDA's streamlined 505(b)(2) regulatory pathway, potentially accelerating the approval process [4] Collaboration and Research - Silo Pharma collaborates with leading universities and laboratories for its research initiatives [6] - Frontage Laboratories, a global CRO, is involved in the safety and toxicology study for SPC-15, enhancing the company's research capabilities [5]

For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-41512 SILO PHARMA, INC. (Exact name of registrant as specified in its charter) | Nevada | 27-3046338 | | --- | --- ...

Core Viewpoint - Silo Pharma, Inc. announced positive preclinical results for SP-26, an extended-release ketamine implant, indicating its potential as a safe and effective treatment for fibromyalgia [1][2]. Study Results - All study endpoints were met, including survival, clinical observations, body weight stability, neurological assessments, and histopathological evaluation [2]. - No implant-related adverse events were observed, with animals maintaining a healthy weight and normal neurological behavior throughout the study [3]. - Ketamine was steadily released post-implantation, achieving peak drug levels within 1 hour and sustaining plasma concentrations for up to 22 days [3]. Safety and Tolerability - Both SP-26 formulations elicited only minimal to mild chronic inflammation at the implant sites, with no significant differences based on dose or formulation [4]. - The design of SP-26 aims to provide sustained, sub-psychedelic levels of ketamine in an abuse-deterrent format, aligning with FDA safety requirements for potential at-home therapeutic designation [5]. Product Overview - SP-26 is a ketamine-based injectable dissolvable polymer implant intended for chronic pain and fibromyalgia treatment, designed to regulate dosage and time release safely [5]. - If clinically successful, SP-26 could qualify for the FDA's streamlined 505(b)(2) regulatory pathway for drug approval [5]. Company Background - Silo Pharma Inc. focuses on addressing underserved conditions, including chronic pain and psychiatric disorders, with a portfolio that includes programs for PTSD and preclinical assets targeting Alzheimer's disease and multiple sclerosis [6].